Antibody Drug Conjugate market, Industry Analysis, and Forecast to 2035

The potential of antibody drug conjugates for the treatment of various disease indications, including cancer, is being slowly recognized in the pharmaceutical sector. Specifically, the success of these products can be attributed to their ability to effectively identify and eliminate diseased cells, along with low risk of side effects.

The financial opportunity within the antibody drug conjugate market has been analyzed across the following segments:

 Target Disease Indication
 Acute Lymphoblastic Leukemia
 Breast Cancer
 B-Cell Lymphoma
 Cervical Cancer
 Gastric Cancer
 Lung Cancer
 Multiple Myeloma
 Renal Cancer
 Other Target Disease Indications

 Therapeutic Area
 Hematological Cancer
 Solid Tumor

 Linker
 Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (Acbut)
 Maleimide
 Maleimidocaproyl
 Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate
 Tetrapeptide-Based Linker
 Valine-Alanine
 Valine-Citrulline
 Other Linkers

 Payload
 DM1
 DM4
 Duocarmycin
 Monomethyl auristatin E (MMAE)
 Monomethyl auristatin F (MMAF)
 Ozogamicin
 SG3199
 SN-38 / Irinotecan
 Other Payloads

 Target Antigen
 BCMA (TNFRSF17 / BCM)
 CD19
 CD22
 CD30
 CD79b
 CEACAM5
 HER-2 (ERBB2)
 Nectin 4
 Tissue factor
 TROP-2
 Other Target Antigen

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific and Rest of the World

The Antibody Drug Conjugate Market (7th Edition), 2023-2035 report features the following companies, which we identified to be key players in this domain:
 ADC Therapeutics
 Astellas Pharma
 AstraZeneca
 Byondis
 Daiichi Sankyo
 Genentech
 Gilead Sciences
 ImmunoGen
 Pfizer
 RemeGen

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Target Competitiveness Analysis

6. Company and Drug Profiles

7. Clinical Trial Analysis

8. Key Opinion Leaders

9. Combination Therapies

10. Partnerships and Collaborations

11. Funding and Investment Analysis

12. Patent Analysis

13. Academic Grants Analysis

14. Key Commercialization Strategies

15. Promotional Analysis

16. Success Protocol Analysis

17. Novel Conjugation and Linker Technology Platforms

18. Assessment of Non-Clinical Data First in Human Dosing

19. Cost Price Analysis

20. Case Study 1: Contract Manufacturing of Antibody-Drug Conjugates

21. Case Study 2: Companion Diagnostics for Antibody-Drug Conjugate Therapeutics

22. SWOT Analysis

23. Market Sizing and Opportunity Analysis

24. Executive Insights

25. Conclusion

26. Appendix 1: Tabulated Data

27. Appendix 2: List of Companies and Organizations

To view more details on this report, click on the link:
https://www.rootsanalysis.com/....reports/view_documen

Learn from experts: do you know about these emerging industry trends?
Digital Therapies: The “Digital Pills” of current generation
Medical Device Coatings and Modification Technologies

Learn from our recently published whitepaper: -
Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

#antibodydrugconjugatemarketshare #antibodydrugconjugatemarkettrends #antibodydrugconjugates #adctherapeutics #antibodydrugconjugatecompanies